Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung

Lung Cancer ◽  
1986 ◽  
Vol 2 (4) ◽  
pp. 268
Keyword(s):  
Cell Carcinoma ◽  
Solid Tumors ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Acute Nonlymphocytic Leukemia ◽  
Intensive Chemotherapy

scholarly journals Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung

Blood ◽  
1985 ◽  
Vol 66 (6) ◽  
pp. 1393-1397 ◽  
Author(s):  
J Pedersen-Bjergaard ◽  
K Osterlind ◽  
M Hansen ◽  
P Philip ◽  
AG Pedersen ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Solid Tumors ◽  
Small Cell Carcinoma ◽  
Bone Marrow Cells ◽  
Cumulative Risk ◽  
Small Cell ◽  
Acute Nonlymphocytic Leukemia ◽  
Kaplan Meier ◽  
Future Therapy ◽  
Very High

Abstract Six of 796 patients treated with intensive combination chemotherapy for small cell carcinoma of the lung developed overt acute nonlymphocytic leukemia (ANLL) (three patients) or preleukemia with severe refractory cytopenia and clonal cytogenetic abnormalities in bone marrow cells (three patients). The latent period to development of preleukemia or leukemia was less than two years in four of the six patients. The cumulative risk of preleukemia and leukemia according to a Kaplan-Meier estimate was 14.0% +/- 6.9% (mean +/- SE) four years after the start of treatment. The relative risk of overt ANLL was 77, since three cases were observed v 0.039 cases expected, based on the age- and sex- specific incidence of acute nonlymphocytic leukemia in the general Danish population. The risk of secondary solid tumors was not increased. The possible causes of the exceptionally early appearance and very high cumulative risk of leukemic complications found in the present study, as compared to previous experience in other malignant diseases, is discussed, including the implications for future therapy of patients with small cell lung cancer.

scholarly journals Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung

Blood ◽  
1985 ◽  
Vol 66 (6) ◽  
pp. 1393-1397
Author(s):  
J Pedersen-Bjergaard ◽  
K Osterlind ◽  
M Hansen ◽  
P Philip ◽  
AG Pedersen ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Solid Tumors ◽  
Small Cell Carcinoma ◽  
Bone Marrow Cells ◽  
Cumulative Risk ◽  
Small Cell ◽  
Acute Nonlymphocytic Leukemia ◽  
Kaplan Meier ◽  
Future Therapy ◽  
Very High

Six of 796 patients treated with intensive combination chemotherapy for small cell carcinoma of the lung developed overt acute nonlymphocytic leukemia (ANLL) (three patients) or preleukemia with severe refractory cytopenia and clonal cytogenetic abnormalities in bone marrow cells (three patients). The latent period to development of preleukemia or leukemia was less than two years in four of the six patients. The cumulative risk of preleukemia and leukemia according to a Kaplan-Meier estimate was 14.0% +/- 6.9% (mean +/- SE) four years after the start of treatment. The relative risk of overt ANLL was 77, since three cases were observed v 0.039 cases expected, based on the age- and sex- specific incidence of acute nonlymphocytic leukemia in the general Danish population. The risk of secondary solid tumors was not increased. The possible causes of the exceptionally early appearance and very high cumulative risk of leukemic complications found in the present study, as compared to previous experience in other malignant diseases, is discussed, including the implications for future therapy of patients with small cell lung cancer.

Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung.

1984 ◽  
Vol 2 (5) ◽  
pp. 385-390 ◽  
Author(s):  
L Y Chak ◽  
B I Sikic ◽  
M A Tucker ◽  
R C Horns ◽  
R S Cox
Keyword(s):  
Relative Risk ◽  
Acute Leukemia ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Confidence Limit ◽  
Small Cell ◽  
Acute Nonlymphocytic Leukemia ◽  
Actuarial Risk

A group of 158 patients with small cell carcinoma of the lung were followed for 174.5 person-years of observation to determine the risk of acute leukemia. Three cases of acute nonlymphocytic leukemia were observed at 2.3, 2.7, and 3.0 years. The relative risk of developing leukemia was 316 (95% confidence limit, 76-818) and the actuarial risk was 25% +/- 13% at 3.1 years. The relative risk for leukemia was significantly increased in these patients (p less than 0.0001).

scholarly journals Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung

Cancer ◽  
1985 ◽  
Vol 56 (12) ◽  
pp. 2771-2778 ◽  
Author(s):  
Brenda Shank ◽  
Howard Scher ◽  
Basil S. Hilaris ◽  
Carl Pinsky ◽  
Michelle Martin ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
High Dose ◽  
Intensive Chemotherapy

scholarly journals Small Cell Carcinoma of the Larynx Treated by Concurrent Chemoradiotherapy: A Case Report

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Susumu Nakahara ◽  
Norihiko Takemoto ◽  
Hidenori Inohara
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Organ Preservation ◽  
Concurrent Chemoradiotherapy ◽  
Complete Response ◽  
Small Cell ◽  
Intensive Chemotherapy ◽  
Rare Entity ◽  
Carcinoma Of The Larynx ◽  
First Interview

Small cell carcinoma (SmCC) generally occurs in the lung and extrapulmonary SmCC is a relatively rare entity. Here, we present a case of a 42-year-old male with SmCC of the larynx diagnosed as cT3N0M0. Concurrent chemoradiotherapy using cisplatin (CDDP) and etoposide (VP-16) was given, which achieved complete response (CR). Lung metastasis became evident in 16 months whereas the locoregional control remained good. In spite of intensive chemotherapy using CDDP and irinotecan (CPT-11), the patient died of disease in 34 months after the first interview. Since the prognosis of laryngeal SmCC is extremely poor, organ preservation therapy should be considered instead of radical laryngectomy.

Sign in / Sign up

Export Citation Format

Share Document